The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Coordination of Clinical and Biological Collections for the, 2011Coordination of Clinical and Biological Collections for the LRRK2 Cohort Consortium
Objective/Rationale:
MJFF is funding multiple international LRRK2 cohorts to gain insight into the relationship of this genetic mutation to Parkinson’s disease. Using standardized methods... -
Therapeutics Development Initiative, 2011Pharmacological Testing of Nurr1 Agonists in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
Sanofi-aventis has identified Nurr1 receptor agonists whose in vitro pharmacological activity, together with literature data, indicate that Nurr1 agonists could provide a novel... -
MJFF Research Grant, 2011Drug Rescue of PINK1 Kinase Activity - A New Therapeutic Modality For Treating PD
Objective/Rationale:
Many genetic disorders are caused by the loss of a functional protein which protects cells from disease. These disorders are difficult to treat with drugs because most drugs block... -
Target Validation, 2011Gene delivery of miRNAs to reduce alpha synuclein: a new therapy for PD
Objective/Rationale:
Alpha synuclein is a protein that in excessive amounts is implicated in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature... -
Target Validation, 2011Overexpression of CSPalpha Using Viral Vectors in the Striatum of a-Syn 1-120 Transgenic Pre-clinicalModel
Objective/Rationale:
Research data have recently indicated that pathology in Parkinson’s disease (PD) starts at the synapse, the part of the neurons where release of dopamine occurs, dysfunction of... -
Rapid Response Innovation Awards, 2011Role of Striatal-Enriched Protein Tyrosine Phosphatase 61 (STEP61) in Parkinson's Disease
Objective/Rationale:
The Park2 gene product parkin is implicated in both genetic and sporadic forms of Parkinson’s disease (PD). Defective parkin function leads to the accumulation of toxic proteins...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.